DK1140026T3 - Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme - Google Patents

Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme

Info

Publication number
DK1140026T3
DK1140026T3 DK99960556T DK99960556T DK1140026T3 DK 1140026 T3 DK1140026 T3 DK 1140026T3 DK 99960556 T DK99960556 T DK 99960556T DK 99960556 T DK99960556 T DK 99960556T DK 1140026 T3 DK1140026 T3 DK 1140026T3
Authority
DK
Denmark
Prior art keywords
preparing
same
receptor antagonist
biodegradable polymer
serotonin receptor
Prior art date
Application number
DK99960556T
Other languages
Danish (da)
English (en)
Inventor
Rachel S Kohn
Stephen J Hanley
Stephen J Comiskey
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK1140026T3 publication Critical patent/DK1140026T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
DK99960556T 1998-12-16 1999-11-22 Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme DK1140026T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16

Publications (1)

Publication Number Publication Date
DK1140026T3 true DK1140026T3 (da) 2006-01-02

Family

ID=22793267

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99960556T DK1140026T3 (da) 1998-12-16 1999-11-22 Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme

Country Status (35)

Country Link
EP (1) EP1140026B1 (xx)
JP (1) JP4759141B2 (xx)
KR (1) KR100707710B1 (xx)
CN (1) CN1195497C (xx)
AP (1) AP1769A (xx)
AR (1) AR021652A1 (xx)
AT (1) ATE303795T1 (xx)
AU (1) AU770673B2 (xx)
BG (1) BG65500B1 (xx)
BR (1) BR9916276A (xx)
CA (1) CA2355077C (xx)
CR (1) CR6424A (xx)
CZ (1) CZ301947B6 (xx)
DE (1) DE69927177T2 (xx)
DK (1) DK1140026T3 (xx)
EA (1) EA004502B1 (xx)
EE (1) EE200100314A (xx)
ES (1) ES2245128T3 (xx)
HK (1) HK1041645B (xx)
HR (1) HRP20010446A2 (xx)
HU (1) HU226586B1 (xx)
ID (1) ID28909A (xx)
IL (2) IL143761A0 (xx)
ME (2) ME00066B (xx)
NO (1) NO20012981L (xx)
NZ (1) NZ511962A (xx)
OA (1) OA11728A (xx)
PL (1) PL196822B1 (xx)
RS (1) RS50123B (xx)
SK (1) SK285812B6 (xx)
TR (1) TR200101759T2 (xx)
TW (1) TWI221418B (xx)
UA (1) UA73101C2 (xx)
WO (1) WO2000035423A1 (xx)
ZA (1) ZA200104899B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
WO2002075273A2 (en) * 2001-03-20 2002-09-26 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
PL364054A1 (en) * 2001-05-23 2004-12-13 Hexal Ag Homogenised product for implants and microparticles
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
PL1797871T3 (pl) * 2004-09-21 2015-07-31 Shandong luye pharmaceutical co ltd Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2720108C (en) 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
KR101456741B1 (ko) * 2008-09-18 2014-10-31 퍼듀 퍼머 엘피 폴리(e-카프로락톤)을 포함하는 제약 투여 형태
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
AU2020417058A1 (en) * 2019-12-31 2022-08-11 Wanka Tanka Ltd. Extended release plastic formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
CH679207A5 (xx) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
DE69133136T2 (de) * 1990-05-16 2003-06-18 Southern Research Institute, Birmingham Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
AU652759B2 (en) * 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
WO1992018106A1 (en) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Method of manufacturing solid dispersion
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ,インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法

Also Published As

Publication number Publication date
CA2355077C (en) 2009-05-26
CN1195497C (zh) 2005-04-06
HK1041645A1 (en) 2002-07-19
HU226586B1 (en) 2009-04-28
TR200101759T2 (tr) 2001-12-21
EE200100314A (et) 2002-08-15
MEP19408A (en) 2010-06-10
ID28909A (id) 2001-07-12
AU770673B2 (en) 2004-02-26
NO20012981D0 (no) 2001-06-15
DE69927177D1 (de) 2005-10-13
ME00066B (me) 2010-06-10
EA200100551A1 (ru) 2001-10-22
DE69927177T2 (de) 2006-06-08
HK1041645B (zh) 2005-07-29
YU41401A (sh) 2003-12-31
BG105591A (en) 2002-01-31
CR6424A (es) 2004-02-26
EP1140026B1 (en) 2005-09-07
IL143761A0 (en) 2002-04-21
SK285812B6 (sk) 2007-08-02
EP1140026A1 (en) 2001-10-10
CA2355077A1 (en) 2000-06-22
JP4759141B2 (ja) 2011-08-31
NO20012981L (no) 2001-07-27
PL196822B1 (pl) 2008-02-29
AP2001002198A0 (en) 2001-09-30
ZA200104899B (en) 2002-09-16
WO2000035423A9 (en) 2002-08-22
WO2000035423A1 (en) 2000-06-22
HRP20010446A2 (en) 2002-06-30
EA004502B1 (ru) 2004-04-29
RS50123B (sr) 2009-03-25
SK8282001A3 (en) 2001-11-06
UA73101C2 (en) 2005-06-15
HUP0105048A2 (hu) 2002-05-29
KR20010082359A (ko) 2001-08-29
JP2002532408A (ja) 2002-10-02
NZ511962A (en) 2003-06-30
AP1769A (en) 2007-08-22
BG65500B1 (bg) 2008-10-31
AR021652A1 (es) 2002-07-31
KR100707710B1 (ko) 2007-04-18
BR9916276A (pt) 2001-09-04
ES2245128T3 (es) 2005-12-16
CN1330536A (zh) 2002-01-09
OA11728A (en) 2005-02-01
TWI221418B (en) 2004-10-01
AU1742500A (en) 2000-07-03
PL348233A1 (en) 2002-05-20
HUP0105048A3 (en) 2002-09-30
IL143761A (en) 2006-08-01
ATE303795T1 (de) 2005-09-15
CZ301947B6 (cs) 2010-08-11
CZ20012157A3 (cs) 2001-09-12

Similar Documents

Publication Publication Date Title
DK1140026T3 (da) Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme
CY2010003I1 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
ATE312819T1 (de) 4,4-biarylpiperidinederivate mit opioid-receptor- wirkung
NO20021633D0 (no) Kjöretöymontert plast-trommel for betongblanding og fremgangsmåter for fremstilling av samme
DE60026451D1 (de) Informationsverteilungsvorrichtung, Informationsempfangsgerät und Informationsverteilungsverfahren
DE60026169D1 (de) Selektive neurokinin-antagonisten
DE69734833D1 (de) Vitronektin rezeptor antagonisten
DE60037977D1 (de) Hydrogenierte vinylaromatische polymerschaumstoffe
DE69917815D1 (de) Polymere zusammensetzung
NO20015658L (no) Polymermaterialer
NO20004503L (no) Vitronectin-reseptor-antagonister
DE60030135D1 (de) Carboxylierte polymerzusammensetzung
NO20003823D0 (no) Superabsorberende polymernettverk
DK1225802T3 (da) Anordning til sortering af fisk
FR2801892B1 (fr) Composition de polymeres
NO20020644D0 (no) Nye integrinreseptor-antagonister
DE69815835D1 (de) Schäumbare polymerzusammensetzung
ATE288940T1 (de) Polymerzusammensetzung
DK1047666T3 (da) Nye fremgangsmåder til fremstilling af ketiminer
DK1146874T3 (da) Vitronectinreceptoragonist
NO983972D0 (no) Polymermateriale med lav densitet
DK0943650T3 (da) Sammensætning på basis af ethylenpolymer, fremgangsmåde til fremstilling heraf og anvendelse heraf
NO20021295D0 (no) Nikotinsyreacetylcholin-reseptor
DE69917392D1 (de) Kristalline Polymerzusammensetzung
DK1088817T3 (da) Fremgangsmåde til fremstilling af 3-acyl-indoler